Utilization of CF Medications before and after ETI
Through examination of our pharmacy records in the pre- and post-ETI
periods, we identified 311 individuals who prescribed any CFTR modulator
between November 2016 and August 2021. Of that group, 235 were
prescribed ETI (at least three medication fills), of whom 112 had lung
function values available before and after starting ETI. Demographic
features of the groups are shown in Table 1 . All CFTR
modulators had average MPRs >95%.
In all PwCF on ETI, average MPR for Dorn, HTS, and PERT in the pre-ETI
period were 37±4.6%, 46±6.4%, and 40±.3%, respectively. Some
individuals filled prescriptions outside of our pharmacy, which could
yield inaccurate results for MPR. To avoid this inaccuracy, we analyzed
the data within a subset of PwCF who used the UNC mail-order pharmacy
regularly pre-ETI, defined as MPR>0.8. (n=37 Dorn, 46 HTS,
52 Enz). In this subset, MPR declined significantly for all medications
post-ETI (Fig. 1A ).